Alzamend Neuro Stock (NASDAQ:ALZN)


OwnershipFinancialsChart

Previous Close

$3.00

52W Range

$2.75 - $135.54

50D Avg

$4.14

200D Avg

$9.35

Market Cap

$2.35M

Avg Vol (3M)

$1.64M

Beta

-0.28

Div Yield

-

ALZN Company Profile


Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

4

IPO Date

Jun 15, 2021

Website

ALZN Performance


ALZN Financial Summary


Apr 24Apr 23Apr 22
Revenue---
Operating Income$-9.94M$-14.87M$-12.32M
Net Income$-9.95M$-14.88M$-12.40M
EBITDA$-9.94M$-14.85M$-12.32M
Basic EPS$-14.70$-22.89$-20.92
Diluted EPS$-14.70$-22.89$-20.88

Fiscal year ends in Apr 24 | Currency in USD

Peer Comparison


TickerCompany
BFRIBiofrontera Inc.
ACIUAC Immune S.A.
SYBXSynlogic, Inc.
ENSCEnsysce Biosciences, Inc.
VRPXVirpax Pharmaceuticals, Inc.
DATSDatChat, Inc.
CNTXContext Therapeutics Inc.